Security key
M7071P109
Nasus Pharma Ltd - Common Stock, par value $0.01 per share (NSRX)
CUSIP: M7071P109
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock, par value $0.01 per share
- Total 13F shares
- 4
- Total 13F value
- $14
- Share change
- +4
- SEC-reported price per share
- $3.50
- Number of holders
- 1
- Value change
- +$14
- Number of buys
- 1
- Shares outstanding
- 11,710,811
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
1
Top holders
1
NSRX full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
Nasus Pharma Ltd SEC filings
Nasus Pharma Ltd company facts
Broader feeds
Reporting periods
Holder history for CUSIP M7071P109
Recent filing periods:
Ownership snapshot
Top reported holders of NSRX - Nasus Pharma Ltd - Common Stock, par value $0.01 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Udi Gilboa
Disclosed value leader
Udi Gilboa
Comparable rows
14/14
Latest evidence
31 Mar 2026
3/4/5
13D/G
13F
Lead comparable stake: 21%
13D/G row: Udi Gilboa
Showing 1-6 of 14 holder rows.
Quick read
Udi Gilboa leads the comparable SEC ownership view at 21%.
14 of 14 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Udi Gilboa's linked filing trail.
Comparable ownership
Top 5
Udi Gilboa
21%
Dalia Megiddo
21%
Ronnie Hershman
15%
BALYASNY ASSET MANAGEMENT L.P.
10%
Capital Point Ltd.
6.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 14 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Udi Gilboa |
3/4/5
13D/G
Founder & Executive Chairman
|
21%
from 13D/G
|
$17,609,724
1,924,476 shares
|
— | 18 Mar 2026 |
| Dalia Megiddo |
3/4/5
13D/G
Chief Development Officer, Director, Founder · Dr. Dalia Megiddo
|
21%
from 13D/G
|
$17,331,479
1,894,068 shares
|
— | 18 Mar 2026 |
| Ronnie Hershman |
3/4/5
13D/G
Director · Dr. Ronnie Hershman
|
15%
from 13D/G
|
$12,247,471
1,338,463 shares
|
— | 18 Mar 2026 |
| BALYASNY ASSET MANAGEMENT L.P. |
13D/G
13F
Company
|
10%
|
$2,714,191
1,169,910 shares
|
$0 | 31 Mar 2026 |
| Capital Point Ltd. |
13D/G
|
6.4%
|
—
575,129 shares
|
$0 | 14 Aug 2025 |
| Funicular Funds, LP |
13D/G
|
5.2%
|
$3,309,730
612,913 shares
|
$0 | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
1
Shares
4
Rows available
1
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
9
Q2 2026 holders
1
Holder diff
-8
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend